Business Wire

OTICON-MEDICAL

Share
Oticon Medical’s Sentio™ System Receives Regulatory Clearance in the US

Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240712765107/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Sentio System includes an external Sentio 1 Mini sound processor and a Sentio Ti Implant placed under the skin. (Photo: Business Wire)

The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date1.

While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative keeping the skin intact. The Sentio System offers an additional solution for patients and supports our commitment to "freedom of choice."

“With the launch of Sentio System, we provide best-in-class and the smallest active transcutaneous system. More importantly, Oticon Medical now offers a complete portfolio of bone-anchored hearing systems. This portfolio meets the needs of patients and customers, and fits diverse clinical settings and global reimbursement schemes for the treatment. We strongly believe that offering a broad portfolio is the path to achieving our mission to "Help more people" and give more potential users the quality of life improvements these systems offer”, says René Govaerts, President & General Manager, Oticon Medical.

The Sentio 1 Mini is designed with a focus on user comfort and ease of use. The device's design and slim profile make it 26% lighter than an alternative1. It gives access to a 360-degree sound experience and offers the widest bandwidth of 9.5kHz.

Sentio Ti is a SuperPowerful implant developed to support patient’s progressive hearing loss, without the need for additional surgeries. Sentio Ti is designed and verified for a higher maximum force output, so that patients can rely on its ability to handle more powerful sound processors2. From a surgeon’s perspective, the implant is designed for surgical flexibility, ensuring a straightforward procedure.

Sentio System is indicated for candidates aged 12 and older who have been diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.

This launch marks a significant milestone for Oticon Medical, as it continues to deliver the innovative hearing solutions that help people live life to the fullest.

For more information visit www.oticonmedical.com.

Not all products are available in all markets. Product availability and indications are subject to regulatory approval and may vary depending on the market.

About Oticon Medical

Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. For more than a decade, we have made bone anchored hearing systems more accessible by simplifying the treatment for physicians, audiologists, and patients alike.

We believe that patients and hearing care professionals should be able to choose the best possible solution at any time along the patient journey. We call it “Freedom of Choice” and it has always been paramount to Oticon Medical. This is the reason why our solutions are designed to be compatible whenever possible. As a result, an implant from Oticon Medical stands as a true testament to our unwavering lifelong support.

We work collaboratively with professionals to ensure that every solution we create is designed with our users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live life to the fullest – now and in the future.

Because we know how much sound matters.

References
1 Sentio implant and sound processor physical features and comparison to other devices (Doc-00123204)
2 275144en Product Information Sentio 1 Mini

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240712765107/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global and Eni Announce 20-Year LNG Sales and Purchase Agreement16.7.2025 13:00:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and Eni S.P.A. of Italy announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 2 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. This deal marks Eni’s first ever long-term agreement with a U.S. LNG producer. To date, approximately 13.5 MTPA of CP2 Phase One has been sold, raising the total contracted capacity for all of Venture Global’s projects to 43.5 MTPA. To date, Venture Global has supplied Italy with nearly 40 cargoes of U.S. LNG from its Calcasieu Pass and Plaquemines LNG facilities. “We are honored that Eni, a leading innovator and global gas player, has chosen Venture Global as their first American LNG supplier. Italy is an important ally and trading partner to the United States, and we are grateful for the trust of Eni as our newest customer. This deal marks a significant milestone for the company and is further recognition of our

Veranex Unveils MedTech’s First Innovation CRO (iCRO)—Redefining R&D in a Capital‑Tight Market16.7.2025 13:00:00 CEST | Press release

Veranex, a global provider of product development and contract research services, today introduced the industry’s first Innovation CRO (iCRO)—an integrated development and research platform engineered to move medical devices and in-vitro diagnostics (IVDs) from concept to commercial success faster, with tighter budget control and a built-in path to payer adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716366338/en/ Veranex launches Innovation CRO for device and diagnostics. iCRO: Innovation Without Waste The Veranex iCRO model is built on four core pillars: Speed & Capital Efficiency – Integrated teams and workflows can cut 3–6 months per development phase and reduce budget variance 18 percent versus transactional (traditional) outsourcing. Flexible partnership tiers—Full Stack, Stage Select, and Strategic Augment—let sponsors deploy only the iCRO services they need while retaining velocity. Evidence Integration

Pluto Labs' 'Strategic Efficiency' AI Outperforms Google & Anthropic Models at a Fraction of the Cost16.7.2025 12:47:00 CEST | Press release

— Achieves decisive victory in key scientific benchmarks, delivering highly practical and experimentally testable ideas with unparalleled cost-efficiency. Global commercial launch slated for Q3 2025, leveraging an existing platform of 170,000 researchers. In the global race to create an 'AI Scientist' capable of independent scientific discovery, Korean startup Pluto Labs is making significant waves. While tech giants like Google and Anthropic define competitive strength by sheer computing power, Pluto Labs introduces 'Scinapse AI,' a groundbreaking model that develops a more effective AI Scientist at just one-tenth of the usual computational cost, achieving overwhelming performance against top models in blind evaluations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715211709/en/ GRAPH: Scientific Idea Generation Performance Comparison - Scinapse AI vs. Google Gemini 2.5 Pro vs. Claude Opus 4 (Evaluation conducted by Pl

Aude Gandon Appointed Chief Digital & Marketing Officer, The Estée Lauder Companies16.7.2025 12:45:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) announced today that Aude Gandon has been appointed Chief Digital & Marketing Officer (CDMO), effective August 1, 2025. Ms. Gandon will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company's Executive Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716106615/en/ Aude Gandon, Chief Digital & Marketing Officer (CDMO), The Estée Lauder Companies In this newly created role, Ms. Gandon will lead the transformation of the company’s digital, marketing and media ecosystem, shaping end-to-end strategies across its powerful brand portfolio, and will oversee global digital commerce. Her appointment reflects the company’s commitment to evolving its consumer-centric approach and strengthening marketing as a commercial growth engine. “Aude is an exceptional and accomplished global marketing leader with extensive experience transformin

Prodalim Expands its Natural Ingredients Portfolio with the Launch of Coloring Foodstuffs and Natural Colors Product Lines, Enhancing Innovation in Upcycled Products16.7.2025 12:18:00 CEST | Press release

Prodalim, a global leader in juice solutions and specialty ingredients, announces the launch of its Coloring Foodstuffs and Natural Colores portfolio, marking a milestone in its commitment to delivering clean-label, plant-based, upcycled product innovations for the food and beverage industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716821011/en/ These natural color solutions are designed for seamless integration into a wide range of applications, including beverages, dairy, plant-based products, bakery, and confectionery. They offer vibrant visual appeal without compromising on performance, health standards, regulatory compliance, or consumer trust. Developed based on strict quality standards, Prodalim’s Coloring portfolio delivers optimal light resistance, pH stability, and thermal performance, addressing real-world formulation challenges while enhancing naturality, clean label credentials, and full “tree-to-table

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye